Nara Organics recalls baby formula sold at Target after multistate infant botulism outbreak

Nara Organics has recalled its Whole Milk Organic Powdered Infant Formula nationwide after federal authorities linked the product to a multistate infant botulism investigation.

Three infants in California, Pennsylvania and Washington became ill after consuming the formula, according to the research packet. The babies were ages 2 to 5 months, and all three were hospitalized and treated with BabyBIG, the standard therapy for infant botulism.

The recall was announced on June 14, 2026, and applies to product sold at Target stores and on Nara.com. The company described the action as precautionary after being notified by the FDA about the illnesses.

What officials said

The CDC has told parents and caregivers to stop using the formula immediately. Families with opened cans were told to record the lot number and use-by date, mark the can DO NOT USE, and keep it separate for at least a month before disposal if no symptoms appear.

Infant botulism is rare, but it can be serious in babies under 1 year old. Symptoms can include constipation, poor feeding, weak muscle tone, drooping eyelids, difficulty swallowing and breathing problems.

The product was manufactured in Europe but sold in the United States. Officials have not yet confirmed whether the formula itself was the source of contamination, and leftover product from affected homes or states is being tested.

Timeline and response

Federal reporting indicates the first known illnesses began in April 2026. Cases continued through May before the recall became public on June 14.

CT Insider reported the recall earlier in the morning of June 14, and the Associated Press later published a broader report on the nationwide action and outbreak response.

The FDA said Nara Organics formula accounts for less than 1% of U.S. infant formula sales, so shortages are not expected. That should limit broader supply disruption even as parents check products at home.

The recall adds to already heightened consumer sensitivity around infant formula safety. Public-health officials are still trying to determine how the contamination may have occurred and whether additional cases emerge.

For now, the central guidance remains the same: stop using the recalled formula, save the package details if possible, and seek immediate medical care if an infant shows possible botulism symptoms.

What remains unknown

Investigators are still waiting on laboratory results from leftover formula. Those results should help determine whether the product was the source of the outbreak or whether another link explains the illnesses.

Officials are also continuing to look for any additional cases. If no new illnesses are identified and testing narrows the source, the recall may settle into a more defined public-health response rather than an expanding outbreak.